The Ras association domain family protein1 isoform A (RASSF1A) is a well-known tumor-suppressor protein frequently inactivated in various human cancers. Consistent with its function as a molecular scaffold protein, referred to in many studies, RASSF1A prevents initiation of tumorigenesis, growth, and dissemination through different biological functions, including cell cycle arrest, migration/metastasis inhibition, microtubular stabilization, and apoptosis promotion. As a regulator of key cancer pathways, namely Ras/Rho GTPases and Hippo signaling without ignoring strong interaction with microtubules, RASSF1A is indeed one of the guardians of cell homeostasis. To date, as we approach the two decade anniversary of RASSF1A's discovery, this review will summarize our current knowledge on the RASSF1A key interactions as a tumor suppressor and discuss their impact on cell fate during carcinogenesis. This could facilitate a deeper understanding of tumor development and provide us with new strategies in cancer treatment by targeting the RASSF1A pathway. Facts • Influence of the tumor microenvironment on the functionality of RASSF1A. Clinical implications of RASSF1A inactivation Universal silencing of RASSF1A in human cancers Described almost two decades ago as a Ras-GTP binding protein, RASSF1A is one of the prototypical tumorsuppressor genes frequently inactivated in >40 types of human malignancies, including lung, breast, prostate, glioma, neuroblastoma, multiple myeloma, and kidney cancer 1-3. Although promoter hypermethylation and loss